Anaconda Pharma

Existing broad-spectrum antivirals like ribavirine or interferon are not active against HPV-related diseases.  Although there is evidence to support a role for the immune system in the hosts defense against the virus, HPV has developed escape mechanisms that make immunomodulation a poor strategy.

No classical drug targets

HPV does not offer any classical drug’able targets, i.e. receptors or enzymes such as polymerases, reverse-transcriptases or proteases. The only viral enzymatic activity (E1 ATPase/helicase) is not specific enough.

No in-vitro assays

The complex biology of the HPV virus has hampered the development of reliable in vitro viral replication systems and reliable animal models.  Only a few scientific laboratories around the world have developed animal models for papillomavirus infection, a few others are experts on HPV proteins structure, while even fewer have developed efficient assays to test all the steps of HPV replication.

 
Anaconda Pharma has developed a unique and proprietary platform for the discovery of small molecules that disrupt E1/E2 interactions.  Anaconda Pharma’s unique technology platform includes:

• proprietary high definition crystallographic 3-D information on targets,
• proprietary cellular and in vitro screening assays, and
• patented lead molecules & series amenable to optimisation.
  

Furthermore, since papillomavirus genomes are not prone to mutation like other viruses (i.e. HIV, influenza), anti-papillomavirus compounds will not be subject to resistance mechanisms and will remain effective with no emergence of resistant strains.

Anaconda Pharma occupies a unique competitive position in the development of anti-HPV therapeutics.